Founded scientists from the National Cancer Institute , Biolgical Mimetics Inc (BMI) has developed a proprietary core technology - termed Immune Dampening and Refocusing. The approach uses immune dampening and refocusing to combat resistant and emerging diseases for which no effective vaccine exists. The ffort is to improve on the strain or serotype restricted protection of previously tried and currently licensed and used human and veterinary vaccines. Currently, BMI maintains several vaccine development programs targeting virus, parasite, and bacterial pathogens. The immune refocusing technology allows for the creation of unique antigens, which can be used for the induction and selection of unique monoclonal antibodies. Additionally, these antigens can be used for therapeutic, diagnostic, and research purposes. BMI also offers a variety of scientific products and confidential support services designed to assist researchers and institutions in their pursuit of scientific knowledge
